We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Profile: Heinrich Henckel.
- Authors
Louët, Sabine
- Abstract
The article profiles Heinrich Henckel, CEO of the Swiss stock exchange. A lawyer by training, Heinrich Henckel has been schooled in the art of building a strong argument to support his case. Now in his position as CEO of the SWX Swiss Exchange, he asserts that the exchange has everything that a biotech company could wish for when looking to list in Europe. Many investment bankers do recognize the value of listing on the SWX Swiss Exchange, but regard the London Stock Exchange (LSE) as just as attractive. Because biotech companies generally have market capitalizations of less than a billion dollars, LSE and SWX Swiss Exchange provide biotech stocks with greater visibility; in contrast, the U.S. exchanges like NASDAQ are dominated by large-cap companies.
- Subjects
HENCKEL, Heinrich; CHIEF executive officers; STOCK exchanges; INVESTMENT bankers; CAPITAL market; BIOTECHNOLOGY industries
- Publication
Nature Biotechnology, 2005, Vol 23, Issue 7, p773
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0705-773